<DOC>
	<DOCNO>NCT02177175</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , beta blocker ( carvedilol ) heart function treatment anti-HER2 medication ( ) include trastuzumab ( Herceptin ) .</brief_summary>
	<brief_title>Carvedilol Prevention Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging Early Risk Stratification</brief_title>
	<detailed_description>This phase II placebo-controlled study evaluate effect carvedilol , compare placebo , anthracycline/anti-HER2 therapy induce leave ventricular dysfunction patient HER2-positive breast cancer receive adjuvant neoadjuvant therapy . All patient undergo routine cardiac surveillance 2D echocardiogram per standard care multiple time point align closely possible following : pre-anthracycline ( baseline ) , pre-anti-HER2 therapy , 3 , 6 , 9 , 12 month ( +/- 4 week ) initiation anti-HER2 therapy . In case standard care echocardiogram do time point , either due delay anti-cancer therapy due patient 's medical condition , principal investigator determine standard care echocardiogram may use lieu one time point list . Additional speckle track strain analysis perform echocardiogram , blood specimen drawn several time point biomarker analysis . After completion anthracycline treatment prior initiation anti-HER2 therapy , 32 patient abnormal myocardial strain , define global longitudinal strain &lt; 19 % % change baseline &gt; 11 % , randomize 1:1 ratio carvedilol versus placebo . Carvedilol administer twice daily approximately 1 year OR end anti-HER2 therapy , discontinue prior 1 year . Treatment carvedilol placebo group systematically up-titrated week 3 , 6 , 9 ( +/- 1 week ) randomization goal dose 25mg twice daily .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Female Age ≥ 18 year Nonmetastatic histologically confirm primary invasive breast carcinoma Pathologically confirm HER2positive breast cancer Scheduled receive anthracycline chemotherapy follow antiHER2 therapy MSKCC Able willing provide inform consent Willing able comply requirement protocol Able swallow capsule For Aim 2 , patient must meet following criterion : Meet inclusion criterion LVEF &gt; 50 % Abnormal global longitudinal strain ( &lt; 19 % , % decrease ≥ 11 % baseline ) prior initiation plan antiHER2 therapy Heart rate ≥ 50 beat per minute Sitting systolic blood pressure &gt; 90 mmHg Patients exclude randomization Aim 2 study meet follow criterion : Current treatment ACEinhibitors beta blocker Allergies inability tolerate beta blocker previously due bradycardia , hypotension , AV block . Known history NCI CTCAE ( Version 4.0 ) Grade ≥ 2 symptomatic CHF , myocardial infarction within 12 month prior randomization , significant symptom ( Grade ≥ 3 ) relating leave ventricular dysfunction , significant ( moderate severe ) valvular disease , significant cardiac arrhythmia ( Grade ≥ 3 ) Premenopausal woman without negative serum urine pregnancy test within 4 week start treatment Enrollment therapeutic intervention trial Breast Medicine service</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Carvedilol</keyword>
	<keyword>Anthracycline</keyword>
	<keyword>HER2</keyword>
	<keyword>14-099</keyword>
</DOC>